CA2779347A1 — Airflow adaptor for a breath-actuated dry powder inhaler
Assigned to Norton Healthcare Ltd · Expires 2011-05-12 · 15y expired
What this patent protects
An airflow adaptor (200) for a breath-actuated dry powder inhaler. The airflow adaptor comprises a conduit (202) having a proximal end (201) and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, a…
USPTO Abstract
An airflow adaptor (200) for a breath-actuated dry powder inhaler. The airflow adaptor comprises a conduit (202) having a proximal end (201) and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further comprises means (204, 205, 206, 210, 211, 212) for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.